Breakthrough trial aims to stop kidney failure in ICU
NCT ID NCT05468203
Summary
This large global study is testing whether a daily pill called dapagliflozin can prevent severe kidney injury in 3000 critically ill patients admitted to intensive care. Patients are randomly assigned to receive either the active drug or a placebo pill for up to 30 days while in the ICU. The goal is to see if this medication, already used for other conditions, can protect the kidneys and reduce the need for dialysis or prevent death in this high-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Austin Health
RECRUITINGHeidelberg, Victoria, 3084, Australia
Contact
Contact
-
Grampians Health
NOT_YET_RECRUITINGBallarat, Victoria, 3350, Australia
Contact
Contact
Conditions
Explore the condition pages connected to this study.